- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04026191
OVT for Epicondylosis (Tennis Elbow)
A Prospective, Open-Label, Multi-Center Post-Market Clinical Follow-Up Study to Evaluate the Residual Risk of OrthoVisc®-T (OVT) in the Treatment of Chronic Lateral Epicondylosis (Tennis Elbow)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Orthovisc-T is a sterile viscoelastic preparation supplied in a disposable glass syringe containing 2.0 mL of sodium hyaluronate (15 mg/mL) dissolved in physiological saline. The Orthovisc-T device is intended to relieve pain and restore function in tendons affected by chronic lateral epicondylosis. The hyaluronic acid solution provides extracellular supplementation of the elbow with lateral epicondylosis, lubricating and hydrating the affected site, thereby providing the ideal environment for healing of the damaged tissue.
The objective of the study is to evaluate the residual risk of two peri-osteotendinous injections of Orthovisc-T spaced one week apart for the relief of elbow pain and to restore function in patients with lateral epicondylosis.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Praha, Czechia
- FN Motol (University Hospital Motol) Klinika dětské a dospělé ortopedie a traumatologie 2.LF UK a FN v Motole
-
Uherské Hradiště, Czechia
- Medical Plus
-
Ústí nad Labem, Czechia
- "Krajská zdravotní Masarykova nemocnice, Ústí nad Labem Ortopedické oddělení"
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 18 years or older
Diagnosis of chronic lateral epicondylosis defined as:
- Pain reproducible on palpation of the lateral epicondyle / common extensor origin, and
- Pain reproducible during resisted wrist extension
- Failed prior treatment for lateral epicondylosis
- Able and willing to provide signed informed consent.
- Subject must be willing to abstain from other peri-articular treatments of the elbow for the duration of the study.
- Subject is willing to discontinue all analgesics including NSAIDs, except acetaminophen/paracetamol, at least seven days before the treatment injection and through the completion of the study.
- Subject is willing to use only acetaminophen/paracetamol (up to a maximum of 4.0 grams per day per the package insert) for the treatment of joint pain for the duration of the study. At least forty-eight hours prior to the Baseline Visit and each follow-up visit, the subject is willing to discontinue use of acetaminophen/paracetamol.
Exclusion Criteria:
- History of hypersensitivity to any of the ingredients in the hyaluronan
- Infection or skin disease in the area of the injection site or elbow joint
- Subject received a peri-articular injection of Hyaluronic Acid (HA) and/or steroid in either elbow within 6 months of signing the informed consent form (ICF). A subject will be excluded if they are planning to receive an HA or steroid injection (other than the study injection) in either elbow during the course of this study.
- Known inflammatory or autoimmune disorders, or other pre-existing medical conditions that, in the opinion of the investigator, could impact healing or affect the ability of the subject to complete the study and comply with the study requirements.
- Subject is taking medications at the time of signing the ICF which could interfere with the treatment procedure, healing and/or assessments. This includes but is not limited to oral or injectable anticoagulant treatments, anti-aggregant platelet treatment, chronic opioid analgesics. Low dose aspirin used for cardiovascular protection is allowed if a stable regimen is maintained for the duration of the study.
- Subjects who had an oral, intramuscular, intravenous, rectal suppository or topical (excluded in index elbow only) corticosteroid within 30 days of signing the ICF are excluded. Topical corticosteroid use at any site other than the index elbow is allowed.
- Subject is a woman who is pregnant or breastfeeding at the Screening Visit or a woman of child bearing potential who refuses to use effective contraception during the course of the study.
- Subject was involved in any other research study involving an investigational product, or a new application of an approved product, within 60 days of signing the ICF.
- Subject is receiving or in litigation for worker's compensation.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Orthovisc-T
|
Sodium hyaluronate supplied as a 2 mL (15mg/mL) unit dose in a 3 mL glass syringe.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The mean change in Elbow Pain from Baseline to 6 Months
Time Frame: From baseline to 6 months
|
The mean change in Pain After Grip from Baseline to 6 Months as measured with a 0-10 Likert Scale comparing the OVT group to Baseline measurements.
|
From baseline to 6 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- OVT 16-03
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Epicondylitis, Lateral
-
Hospital for Special Surgery, New YorkActive, not recruitingLateral Epicondylitis | Lateral Epicondylitis, Unspecified Elbow | Lateral Epicondylitis, Left Elbow | Lateral Epicondylitis, Right Elbow | Lateral Epicondylitis (Tennis Elbow) Bilateral | Medial Epicondylitis | Medial Epicondylitis, Right Elbow | Medial Epicondylitis, Left ElbowUnited States
-
Singapore General HospitalNot yet recruitingLateral Epicondylitis, Unspecified Elbow
-
McMaster UniversityArthrex, Inc.; The Physicians' Services Incorporated Foundation; Radiological...TerminatedLateral Epicondylitis (Tennis Elbow)Canada, United States
-
Haseki Training and Research HospitalCompletedLateral Epicondylitis (Tennis Elbow)Turkey
-
Siddharth Padia, MDRecruiting
-
University of CadizNot yet recruitingElbow Tendinopathy | Epicondylitis | Epicondylitis, Lateral | Epicondylitis of the Elbow
-
Chuncheon Sacred Heart HospitalRecruitingLateral Epicondylitis of ElbowKorea, Republic of
-
Uskudar State HospitalRecruitingLateral Epicondylitis | Lateral Epicondylitis, Unspecified ElbowTurkey
-
Istanbul Training and Research HospitalCompletedLateral Epicondylitis | Comparing Autologous Blood Corticosteroid and Their Combined Injection for Treating Lateral EpicondylitisTurkey
-
Mennallah Ahmed Mohamed Anwar ElgendyNot yet recruiting
Clinical Trials on OrthoVisc®-T (OVT)
-
cerbomed GmbHCompleted
-
Teva Branded Pharmaceutical Products R&D, Inc.CompletedGrowth Hormone Deficiency
-
Baptist Health South FloridaWilliam Cook AustraliaRecruitingThoracoabdominal Aortic Aneurysm | Aortic Arch AneurysmUnited States
-
St. Jude Children's Research HospitalOxford ImmunotecTerminated
-
Assistance Publique - Hôpitaux de ParisInstitut National de la Santé Et de la Recherche Médicale, FranceCompleted
-
cerbomed GmbHCompleted
-
Wake Forest University Health SciencesTerminatedAcute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Chronic Myeloid Leukemia | Myelodysplastic Syndrome | Immune Deficiency | Lymphomas | Bone Marrow Failure | Osteopetrosis | HemoglobinopathyUnited States
-
Cook Group IncorporatedCompletedAortic Aneurysm | ThoracoabdominalGermany, Sweden
-
European University of MadridUnknown
-
Universitaire Ziekenhuizen KU LeuvenKU LeuvenUnknownHealthy AdultsBelgium